{"id":"placebo-to-adalimumab","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo serves as a control comparator in clinical trials and is used to establish the efficacy of active treatments like adalimumab through comparison. It produces no direct biological effect on disease pathways or molecular targets. Any observed clinical benefit from placebo is attributable to the placebo effect—psychological and contextual factors rather than pharmacological action.","oneSentence":"Placebo is an inert substance with no active pharmacological mechanism.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:01:28.872Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Clinical trial control arm (comparator to adalimumab in various inflammatory and autoimmune conditions)"}]},"trialDetails":[{"nctId":"NCT04870203","phase":"PHASE3","title":"Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Bordeaux","startDate":"2021-07-15","conditions":"Rheumatoid Arthritis","enrollment":160},{"nctId":"NCT07061574","phase":"PHASE1, PHASE2","title":"A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-03-30","conditions":"Type 1 Diabetes, New Onset","enrollment":120},{"nctId":"NCT06996652","phase":"PHASE2","title":"An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)","status":"NOT_YET_RECRUITING","sponsor":"Yale University","startDate":"2026-04","conditions":"REM Sleep Behavior Disorder","enrollment":108},{"nctId":"NCT07423533","phase":"PHASE2","title":"Phase IIb Clinical Study to Assess the Efficacy and Safety of GenSci120 Injection in Patients With Moderately to Severely Active RA Who Have an Inadequate Response to at Least One DMARD","status":"NOT_YET_RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2026-02","conditions":"Rheumatoid Arthritis","enrollment":450},{"nctId":"NCT03153319","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","startDate":"2017-06-05","conditions":"Mucopolysaccharidosis I, Mucopolysaccharidosis II, Mucopolysaccharidosis VI","enrollment":14},{"nctId":"NCT03412747","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2018-01-26","conditions":"Chronic Plaque Psoriasis, Moderate to Severe Plaque Psoriasis","enrollment":478},{"nctId":"NCT03895203","phase":"PHASE3","title":"A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2019-04-03","conditions":"Psoriatic Arthritis","enrollment":852},{"nctId":"NCT02586831","phase":"PHASE1, PHASE2","title":"Diabetes Islet Preservation Immune Treatment","status":"WITHDRAWN","sponsor":"Camillo Ricordi and Jay Skyler","startDate":"2024-06-01","conditions":"Diabetes Mellitus, Type 1, Hypoglycemia, Autoimmune Diseases","enrollment":""},{"nctId":"NCT05814627","phase":"PHASE3","title":"Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2023-06-15","conditions":"Rheumatoid Arthritis","enrollment":487},{"nctId":"NCT02829424","phase":"PHASE4","title":"Multicenter Randomized Double Blind Controlled-study to Assess the Potential of Methotrexate Versus Placebo to Improve and Maintain Response to Anti TNF- Alpha Agents in Adult Patients With Moderate to Severe Psoriasis","status":"TERMINATED","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2017-01-23","conditions":"Psoriasis","enrollment":78},{"nctId":"NCT07151937","phase":"PHASE2","title":"A Study of LAD191 in Adults With Hidradenitis Suppurativa","status":"NOT_YET_RECRUITING","sponsor":"Almirall, S.A.","startDate":"2025-09","conditions":"Hidradenitis Suppurativa","enrollment":200},{"nctId":"NCT03104400","phase":"PHASE3","title":"A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-04-27","conditions":"Psoriatic Arthritis","enrollment":1705},{"nctId":"NCT01385826","phase":"PHASE2, PHASE3","title":"Effect of Adalimumab for the Treatment of Uveitis in Juvenile Idiopathic Arthritis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2011-06-29","conditions":"Uveitis, Juvenile Arthritis","enrollment":34},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT02629159","phase":"PHASE3","title":"A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2015-12-01","conditions":"Rheumatoid Arthritis","enrollment":1629},{"nctId":"NCT06640517","phase":"PHASE3","title":"Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Netakimab in Children With Moderate to Severe Plaque Psoriasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biocad","startDate":"2024-08-08","conditions":"Plaque Psoriasis","enrollment":140},{"nctId":"NCT03816397","phase":"PHASE4","title":"Adalimumab in JIA-associated Uveitis Stopping Trial","status":"COMPLETED","sponsor":"Nisha Acharya","startDate":"2020-03-15","conditions":"Uveitis, JIA","enrollment":87},{"nctId":"NCT03464136","phase":"PHASE3","title":"Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2018-03-29","conditions":"Crohn Disease","enrollment":386},{"nctId":"NCT04655807","phase":"PHASE2","title":"A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease","status":"WITHDRAWN","sponsor":"Janssen Research & Development, LLC","startDate":"2021-03-03","conditions":"Crohn Disease","enrollment":""},{"nctId":"NCT05599347","phase":"PHASE2","title":"Pre-treatment With Azithromycin to Reduce Immunogenicity to to Anti-TNF Agents in Patients With Crohn's Disease","status":"RECRUITING","sponsor":"Rambam Health Care Campus","startDate":"2023-04-24","conditions":"Crohn's Disease Relapse, Biological Substance; Adverse Effect","enrollment":180},{"nctId":"NCT05090124","phase":"NA","title":"Experimental Medicine Studies of the Brain in Patients With Rheumatoid Arthritis REALISE","status":"COMPLETED","sponsor":"NHS Greater Glasgow and Clyde","startDate":"2022-11-04","conditions":"Rheumatoid Arthritis","enrollment":46},{"nctId":"NCT06242652","phase":"PHASE2","title":"A Study to Evaluate 608 in Patients with Ankylosing Spondylitis (AS)","status":"UNKNOWN","sponsor":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","startDate":"2024-03-19","conditions":"Ankylosing Spondylitis","enrollment":250},{"nctId":"NCT05640245","phase":"PHASE2","title":"Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"MoonLake Immunotherapeutics AG","startDate":"2022-12-13","conditions":"Arthritis, Psoriatic","enrollment":207},{"nctId":"NCT03180957","phase":"PHASE2","title":"Repurposing Anti-TNF for Treating Dupuytren's Disease","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2016-03-02","conditions":"Dupuytren's Disease","enrollment":140},{"nctId":"NCT06333210","phase":"PHASE3","title":"Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial Spondyloarthritis (LEVENTA)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biocad","startDate":"2023-12-25","conditions":"Axial Spondyloarthritis","enrollment":421},{"nctId":"NCT05322473","phase":"PHASE2","title":"Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa","status":"COMPLETED","sponsor":"MoonLake Immunotherapeutics AG","startDate":"2022-04-25","conditions":"Hidradenitis Suppurativa","enrollment":234},{"nctId":"NCT01793519","phase":"PHASE4","title":"Stopping TNF Alpha Inhibitors in Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Georgetown University","startDate":"2013-01","conditions":"Rheumatoid Arthritis","enrollment":290},{"nctId":"NCT03759288","phase":"PHASE2, PHASE3","title":"An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2018-12-07","conditions":"Crohn's Disease, IBD","enrollment":89},{"nctId":"NCT04988308","phase":"PHASE2","title":"A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-10-12","conditions":"Hidradenitis Suppurativa","enrollment":151},{"nctId":"NCT02760407","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease","status":"COMPLETED","sponsor":"R-Pharm International, LLC","startDate":"2016-06-06","conditions":"Rheumatoid Arthritis","enrollment":1648},{"nctId":"NCT03259074","phase":"PHASE3","title":"Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-11-30","conditions":"Ankylosing Spondylitis","enrollment":859},{"nctId":"NCT05871086","phase":"PHASE2, PHASE3","title":"Coenzyme Q10 in Juvenile Idiopathic Arthritis Patients","status":"UNKNOWN","sponsor":"Nourhan Elsherif","startDate":"2023-05-01","conditions":"Juvenile Idiopathic Arthritis","enrollment":60},{"nctId":"NCT05020730","phase":"PHASE2","title":"Trial to Determine the Immunomodulatory Activity of PTM-001 in Patients With Hidradenitis Suppurativa","status":"UNKNOWN","sponsor":"Phoenicis Therapeutics","startDate":"2022-05-05","conditions":"Hidradenitis Suppurativa","enrollment":50},{"nctId":"NCT05372939","phase":"PHASE2","title":"Study of the Efficacy and Safety of AMT-101 in Combination With Adalimumab in Subjects With Ulcerative Colitis (MARKET)","status":"COMPLETED","sponsor":"Applied Molecular Transport","startDate":"2021-02-05","conditions":"Ulcerative Colitis","enrollment":51},{"nctId":"NCT04115748","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2019-12-03","conditions":"Psoriatic Arthritis","enrollment":67},{"nctId":"NCT03248531","phase":"PHASE2","title":"A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2017-09-22","conditions":"Hidradenitis Suppurativa","enrollment":90},{"nctId":"NCT02332590","phase":"PHASE3","title":"Efficacy and Safety of Sarilumab and Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (SARIL-RA-MONARCH)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-01-28","conditions":"Rheumatoid Arthritis","enrollment":369},{"nctId":"NCT04705844","phase":"PHASE3","title":"Study of Adalimumab or Placebo in Patients With Mild to Moderate COVID-19 (COMBAAT)","status":"WITHDRAWN","sponsor":"Alachua Government Services, Inc.","startDate":"2021-09","conditions":"Mild to Moderate COVID-19","enrollment":""},{"nctId":"NCT01373151","phase":"PHASE2","title":"Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2011-06","conditions":"Rheumatoid Arthritis","enrollment":418},{"nctId":"NCT02471118","phase":"PHASE2","title":"Osteoarthritis of the Knee, Inflammation, and the Effect of Adalimumab (OKINADA)","status":"COMPLETED","sponsor":"CARE ARTHRITIS LTD.","startDate":"2015-03","conditions":"Osteoarthritis, Knee","enrollment":62},{"nctId":"NCT03607903","phase":"PHASE1, PHASE2","title":"Adalimumab Microneedles in Healthy Volunteers","status":"COMPLETED","sponsor":"Centre for Human Drug Research, Netherlands","startDate":"2018-07-11","conditions":"Pain, Injection Site","enrollment":24},{"nctId":"NCT02694523","phase":"PHASE3","title":"BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-03","conditions":"Psoriasis","enrollment":684},{"nctId":"NCT02171429","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-11-14","conditions":"Ulcerative Colitis","enrollment":358},{"nctId":"NCT02207231","phase":"PHASE3","title":"A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-11-26","conditions":"Psoriasis","enrollment":837},{"nctId":"NCT02163759","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-11-04","conditions":"Ulcerative Colitis","enrollment":358},{"nctId":"NCT02207244","phase":"PHASE3","title":"A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-11-03","conditions":"Psoriasis","enrollment":992},{"nctId":"NCT03823391","phase":"PHASE2","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Participants With Moderate to Severe Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2019-03-27","conditions":"Rheumatoid Arthritis (RA)","enrollment":48},{"nctId":"NCT01166282","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Enthesitis Related Arthritis","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-09","conditions":"Enthesitis Related Arthritis (ERA)","enrollment":46},{"nctId":"NCT01468233","phase":"PHASE3","title":"Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-11","conditions":"Hidradenitis Suppurativa (HS)","enrollment":326},{"nctId":"NCT01468207","phase":"PHASE3","title":"Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-11","conditions":"Hidradenitis Suppurativa (HS)","enrollment":307},{"nctId":"NCT01124838","phase":"PHASE3","title":"Efficacy and Safety of Adalimumab in Subjects With Inactive Uveitis","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-08","conditions":"Uveitis","enrollment":261},{"nctId":"NCT01138657","phase":"PHASE3","title":"Efficacy and Safety of Adalimumab in Patients With Active Uveitis","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-08","conditions":"Uveitis","enrollment":239},{"nctId":"NCT01064856","phase":"PHASE3","title":"Study of Adalimumab in Participants With Peripheral Spondyloarthritis (SpA)","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-02","conditions":"Peripheral Spondyloarthritis","enrollment":165},{"nctId":"NCT01716039","phase":"PHASE2","title":"Pharmacokinetics of Adalimumab With Methotrexate for Treatment of Patients With Ulcerative Colitis (UC)","status":"TERMINATED","sponsor":"Alimentiv Inc.","startDate":"2013-06","conditions":"Ulcerative Colitis","enrollment":22},{"nctId":"NCT04643483","phase":"PHASE3","title":"A Study to Test Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Crohn's Disease","status":"WITHDRAWN","sponsor":"UCB Biopharma SRL","startDate":"2021-06","conditions":"Crohn's Disease","enrollment":""},{"nctId":"NCT02889796","phase":"PHASE3","title":"Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-08-30","conditions":"Rheumatoid Arthritis","enrollment":1759},{"nctId":"NCT01893996","phase":"PHASE4","title":"Study of Adalimumab to Lower Cardiovascular Risk in RA Patients With Well Controlled Joint Disease","status":"COMPLETED","sponsor":"Jonathan Graf","startDate":"2013-07","conditions":"Rheumatoid Arthritis, Cardiovascular Disease","enrollment":63},{"nctId":"NCT02065570","phase":"PHASE3","title":"Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-05-01","conditions":"Crohn's Disease","enrollment":514},{"nctId":"NCT02065622","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-03-27","conditions":"Ulcerative Colitis (UC)","enrollment":952},{"nctId":"NCT00808210","phase":"PHASE2","title":"A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2009-03-05","conditions":"Rheumatoid Arthritis","enrollment":28},{"nctId":"NCT02065557","phase":"PHASE3","title":"Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-10-13","conditions":"Ulcerative Colitis","enrollment":101},{"nctId":"NCT02983227","phase":"PHASE2","title":"A Study to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Rheumatoid Arthritis Enrolled in Study GA29350","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2016-11-30","conditions":"Rheumatoid Arthritis","enrollment":496},{"nctId":"NCT02833350","phase":"PHASE2","title":"Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2016-09-09","conditions":"Rheumatoid Arthritis","enrollment":578},{"nctId":"NCT02808975","phase":"PHASE4","title":"Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-07-18","conditions":"Hidradenitis Suppurativa (HS)","enrollment":206},{"nctId":"NCT02497469","phase":"PHASE3","title":"An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-06-29","conditions":"Colitis, Ulcerative","enrollment":771},{"nctId":"NCT02696785","phase":"PHASE3","title":"A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2016-05-02","conditions":"Spondyloarthritis","enrollment":341},{"nctId":"NCT04154852","phase":"PHASE2","title":"ADalimumab in Persistent Early Oligoarthrits Study (ADEOS)","status":"COMPLETED","sponsor":"University of Leeds","startDate":"2011-06","conditions":"Oligoarthritis","enrollment":22},{"nctId":"NCT01710358","phase":"PHASE3","title":"A Study in Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-10","conditions":"Rheumatoid Arthritis","enrollment":1307},{"nctId":"NCT02198651","phase":"PHASE4","title":"A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-01-05","conditions":"Rheumatoid Arthritis, Musculoskeletal and Connective Tissue Diseases","enrollment":149},{"nctId":"NCT01029847","phase":"PHASE4","title":"Adalimumab in Axial Spondyloarthritis (ASIM) - MRI and Biomarkers in Patients With Spondyloarthritis","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2009-12","conditions":"Spondyloarthritis","enrollment":49},{"nctId":"NCT02499783","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-08-17","conditions":"Crohn's Disease","enrollment":205},{"nctId":"NCT01500278","phase":"PHASE4","title":"Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate","status":"COMPLETED","sponsor":"UCB Pharma SA","startDate":"2011-12","conditions":"Rheumatoid Arthritis","enrollment":915},{"nctId":"NCT02187055","phase":"PHASE4","title":"An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-08","conditions":"Rhematoid Arthritis","enrollment":1152},{"nctId":"NCT02862574","phase":"PHASE2","title":"Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2016-12-15","conditions":"Rheumatoid Arthritis","enrollment":15},{"nctId":"NCT02015793","phase":"PHASE2","title":"Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Two Treatment Modules in Chinese Subjects With Moderate to Severe Crohn's Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-12","conditions":"Crohn's Disease","enrollment":30},{"nctId":"NCT01808118","phase":"PHASE3","title":"Continuing Versus Withdrawing Adalimumab in Maintaining Remission in Non-Radiographic Axial Spondyloarthritis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-04-16","conditions":"Axial Spondyloarthritis","enrollment":673},{"nctId":"NCT01553058","phase":"PHASE4","title":"Vascular Inflammation in Psoriasis Trial (The VIP Trial)","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2012-07","conditions":"Psoriasis, Cardiovascular Disease","enrollment":97},{"nctId":"NCT02019472","phase":"PHASE3","title":"A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-04-04","conditions":"Arthritis, Rheumatoid","enrollment":559},{"nctId":"NCT02150473","phase":"PHASE3","title":"The Effect of Adalimumab Plus Methotrexate (MTX) Versus Placebo Plus MTX on Cartilage in (RA) Patients","status":"TERMINATED","sponsor":"Heinrich-Heine University, Duesseldorf","startDate":"2014-10","conditions":"Rheumatoid Arthritis","enrollment":21},{"nctId":"NCT01251614","phase":"PHASE3","title":"A Double Blind Study in Pediatric Subjects With Chronic Plaque Psoriasis, Studying Adalimumab vs. Methotrexate","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-12","conditions":"Plaque Psoriasis","enrollment":114},{"nctId":"NCT02437253","phase":"PHASE1, PHASE2","title":"Effects of Adalimumab in Mucopolysaccharidosis Types I, II and VI","status":"COMPLETED","sponsor":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","startDate":"2015-05","conditions":"Mucopolysaccharidosis Type I, Mucopolysaccharidosis Type II, Mucopolysaccharidosis Type VI","enrollment":2},{"nctId":"NCT02349451","phase":"PHASE2","title":"A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis (PsA) Who Have an Inadequate Response to Methotrexate (MTX)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-04-28","conditions":"Psoriatic Arthritis","enrollment":240},{"nctId":"NCT01483599","phase":"PHASE2","title":"A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis","status":"COMPLETED","sponsor":"Janssen Inc.","startDate":"2011-11-10","conditions":"Psoriasis","enrollment":293},{"nctId":"NCT01764997","phase":"PHASE3","title":"An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate","status":"TERMINATED","sponsor":"Sanofi","startDate":"2013-04","conditions":"Rheumatoid Arthritis","enrollment":776},{"nctId":"NCT02016482","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-01","conditions":"Nail Psoriasis, Plaque Psoriasis","enrollment":217},{"nctId":"NCT01899755","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability, Immunogenicity, and Pharmacodynamics (PD) of GSK2800528 in Healthy Subjects.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-07-10","conditions":"Psoriasis","enrollment":45},{"nctId":"NCT00480272","phase":"PHASE4","title":"Prospective Study on Intensive Early Rheumatoid Arthritis Treatment","status":"COMPLETED","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2007-05","conditions":"Rheumatoid Arthritis","enrollment":251},{"nctId":"NCT02643654","phase":"PHASE2","title":"MABp1 IN HIDRADENITIS SUPPURATIVA REFRACTORY TO ADALIMUMAB","status":"COMPLETED","sponsor":"Evangelos J. Giamarellos-Bourboulis, M.D.","startDate":"2015-12","conditions":"Hidradenitis Suppurativa","enrollment":20},{"nctId":"NCT01225393","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2010-11","conditions":"Rheumatoid Arthritis","enrollment":211},{"nctId":"NCT01722214","phase":"PHASE4","title":"Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With Psoriasis","status":"COMPLETED","sponsor":"Innovaderm Research Inc.","startDate":"2012-11","conditions":"Psoriasis, Vascular Inflammation, Coronary Atherosclerosis","enrollment":107},{"nctId":"NCT01562951","phase":"PHASE3","title":"Assessment of Mucosal Activity to Improve the Prognosis of Patients With Crohn's Disease Treated With Immunosuppressants","status":"TERMINATED","sponsor":"Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa","startDate":"2012-10","conditions":"Crohn's Disease, Mucosal Inflammation","enrollment":15},{"nctId":"NCT00595413","phase":"PHASE2","title":"Atacicept in Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis (AUGUST II)","status":"COMPLETED","sponsor":"EMD Serono","startDate":"2007-09","conditions":"Rheumatoid Arthritis","enrollment":311},{"nctId":"NCT01783015","phase":"PHASE4","title":"Study of Etanercept in Subjects With Rheumatoid Arthritis Who Have Had an Inadequate Response to Adalimumab or Infliximab Plus Methotrexate","status":"TERMINATED","sponsor":"Pfizer","startDate":"2013-09","conditions":"Rheumatoid Arthritis","enrollment":16},{"nctId":"NCT00660647","phase":"PHASE3","title":"Optimized Treatment Algorithm for Patients With Early Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2007-09","conditions":"Arthritis, Rheumatoid","enrollment":180},{"nctId":"NCT00298272","phase":"PHASE2","title":"Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Biogen","startDate":"2006-05","conditions":"Rheumatoid Arthritis","enrollment":54},{"nctId":"NCT01295814","phase":"PHASE3","title":"Efficacy Study of Adalimumab to Treat Interstitial Cystitis","status":"COMPLETED","sponsor":"ICStudy, LLC","startDate":"2011-03","conditions":"Interstitial Cystitis","enrollment":43},{"nctId":"NCT01004432","phase":"PHASE3","title":"Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)","status":"COMPLETED","sponsor":"Janssen Biotech, Inc.","startDate":"2009-12","conditions":"Arthritis, Arthritis, Rheumatoid, Autoimmune Diseases","enrollment":433},{"nctId":"NCT01646073","phase":"PHASE3","title":"Safety and Efficacy Study of Adalimumab in the Treatment of Plaque Psoriasis","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-08","conditions":"Plaque Psoriasis","enrollment":425},{"nctId":"NCT00939003","phase":"PHASE3","title":"Study of Adalimumab in Patients With Axial Spondyloarthritis","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2009-07","conditions":"Axial Spondyloarthritis","enrollment":192},{"nctId":"NCT00853099","phase":"PHASE3","title":"A Study of Adalimumab in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2009-02","conditions":"Ulcerative Colitis","enrollment":274}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Placebo to adalimumab","genericName":"Placebo to adalimumab","companyName":"Hoffmann-La Roche","companyId":"roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Placebo is an inert substance with no active pharmacological mechanism. Used for Clinical trial control arm (comparator to adalimumab in various inflammatory and autoimmune conditions).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}